Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive characterisation of allograft rejection.
The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression optimisation. However, there is no standard recognition of the usage of this new technology.
The objectives of this project are –
ESOT, with the kind support from CareDx, Eurofins, and Natera will lead projects to foster awareness and education in the field of Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection.
Kidney
Heart & Lung
Liver
This project is possible thanks to the kind support of
Addressing the biggest challenges in transplantation takes teamwork. With an ESOT membership, you’ll continue to be a valued part of Europe’s largest network of dedicated transplant professionals, sharing ideas and collaborating to improve the science and practice of transplantation.